Drug Resistance, Multiple, Bacterial
"Drug Resistance, Multiple, Bacterial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
| Descriptor ID |
D024901
|
| MeSH Number(s) |
G06.099.225.812 G06.225.347.812 G07.690.773.984.269.347.812 G07.690.773.984.300.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Multiple, Bacterial".
- Biological Sciences [G]
- Microbiological Phenomena [G06]
- Bacterial Physiological Phenomena [G06.099]
- Drug Resistance, Bacterial [G06.099.225]
- Drug Resistance, Multiple, Bacterial [G06.099.225.812]
- Drug Resistance, Microbial [G06.225]
- Drug Resistance, Bacterial [G06.225.347]
- Drug Resistance, Multiple, Bacterial [G06.225.347.812]
- Physiological Phenomena [G07]
- Pharmacological and Toxicological Phenomena [G07.690]
- Pharmacological Phenomena [G07.690.773]
- Drug Resistance [G07.690.773.984]
- Drug Resistance, Microbial [G07.690.773.984.269]
- Drug Resistance, Bacterial [G07.690.773.984.269.347]
- Drug Resistance, Multiple, Bacterial [G07.690.773.984.269.347.812]
- Drug Resistance, Multiple [G07.690.773.984.300]
- Drug Resistance, Multiple, Bacterial [G07.690.773.984.300.500]
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Multiple, Bacterial".
This graph shows the total number of publications written about "Drug Resistance, Multiple, Bacterial" by people in this website by year, and whether "Drug Resistance, Multiple, Bacterial" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 3 | 3 | 6 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 5 | 6 |
| 2008 | 7 | 2 | 9 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 3 | 5 |
| 2014 | 2 | 3 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 4 | 6 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Multiple, Bacterial" by people in Profiles.
-
Humphries RM, Janssen H, Hey-Hadavi JH, Hackel M, Sahm D. Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020. Int J Antimicrob Agents. 2023 Feb; 61(2):106724.
-
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Int J Infect Dis. 2022 Dec; 125:250-257.
-
Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, Motyl MR, Sahm DF. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. J Glob Antimicrob Resist. 2022 06; 29:527-533.
-
Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019. Antimicrob Agents Chemother. 2022 02 15; 66(2):e0199021.
-
Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021 06 15; 72(12):2112-2120.
-
Lob SH, Hackel MA, Young K, Motyl MR, Sahm DF. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. Diagn Microbiol Infect Dis. 2021 Aug; 100(4):115421.
-
Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019. BMC Microbiol. 2021 03 06; 21(1):74.
-
Intravia JM, Osterman MN, Tosti R. Antibiotic Management and Antibiotic Resistance in Hand Infections. Hand Clin. 2020 08; 36(3):301-305.
-
Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF, Sato T, Maki H, Yamano Y. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist. 2020 09; 22:738-741.
-
Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018. JAMA Ophthalmol. 2020 05 01; 138(5):439-450.